Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide

#352

Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.

Aim(s): To identify factors associated with tumor control in a group of patients with WDEC treated with lanreotide.

Materials and methods: A retrospective study was conducted in 68 patients with WDEC treated with lanreotide alone, progression-free survival (PFS) being the primary endpoint. The influence of the following factors was searched for by uni- and multivariate analysis: age, gender, discovery mode, origin of the primary tumor, metastatic spread Ki 67 index, grade of uptake on somatostatin receptor scintigraphy, pre-treatment tumor evolutivity, extent of liver involvement, resection of primary tumor, prior treatments, tumor markers.

Conference:

Presenting Author:

Authors: Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V,

Keywords: somatostatin analogs, neuroendocrine, treatment, clinical,

Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide

#219

Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).

Aim(s): To identify factors associated with tumor control in a group of patients with WDEC treated with lanreotide.

Materials and methods: Retrospective study in 68 patients with WDEC treated with lanreotide alone, primary endpoint: PFS. Uni- and multivariate analysis on age, gender, discovery mode, origin of the primary tumor, metastatic spread, Ki-67 index, grade of uptake on SRS, pre-treatment evolutivity, extent of liver involvement, resection of the primary, and tumor markers.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Palazzo M, Catherine L, Guillaume C, Tamara M, Vinciane R,

Keywords: digestive endocrine tumors, lanreotide, tumor growth, Ki-67, liver metastases,